The introduction of gene therapy, such as Voretigene Neparvovec-rzyl-LuxturnaTM for the treatment of biallelic Retinal Pigment Epithelium 65 (RPE65) associated Leber Congenital Amaurosis (LCA), has been a significant development [6–9]. This evidence concerns the gene RPE65 and Leber congenital amaurosis.